Updates are available Correction dated 2024-12-20
Click to view Correction: https://doi.org/10.1038/s41434-024-00487-5
-
Authors
Bouquet, Lucie
Bôle-Richard, Elodie
Warda, Walid
Neto Da Rocha, Mathieu
Trad, Rim
Nicod, Clémentine
Haderbache, Rafik
Genin, Delphine
Ferrand, Christophe https://orcid.org/0000-0003-0119-3919
Deschamps, Marina https://orcid.org/0000-0002-0564-0926
- License Information
-
More Information
Article History
Received: 7 November 2022
Revised: 30 March 2023
Accepted: 18 April 2023
First Online: 12 May 2023
Change Date: 11 October 2024
Change Type: Update
Change Details: There was an error in the supplementary material.
Change Date: 20 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41434-024-00487-5
Competing interests
: MD and CF are co-funders and share holders of CanCell Therapeutics, WW, MNDR, DG and CN are employes of CanCell Therapeutics. The other authors declare no competing interests.
: Donors from the French Blood Establishment provided written informed consent, and the study was conducted in accordance with appropriate ethical guidelines (Declaration of Helsinki) and approved by the local ethics CPP-Est committee (France). AML samples were collected from patients with AML at follow-up or diagnosis included, after consent, in the approved AML samples collection, CAR-LAM, N° CPP: CPP2019-03-022a.
